DE02735262T1 - Schilddrüsenhormon-rezeptor-antagonisten zur behandlung von herzerkrankungen & metabolischen störungen - Google Patents
Schilddrüsenhormon-rezeptor-antagonisten zur behandlung von herzerkrankungen & metabolischen störungen Download PDFInfo
- Publication number
- DE02735262T1 DE02735262T1 DE0001387825T DE02735262T DE02735262T1 DE 02735262 T1 DE02735262 T1 DE 02735262T1 DE 0001387825 T DE0001387825 T DE 0001387825T DE 02735262 T DE02735262 T DE 02735262T DE 02735262 T1 DE02735262 T1 DE 02735262T1
- Authority
- DE
- Germany
- Prior art keywords
- dibromo
- phenyl
- amino
- disease
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940123712 Thyroid hormone receptor antagonist Drugs 0.000 title 1
- 208000019622 heart disease Diseases 0.000 title 1
- 208000030159 metabolic disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 14
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract 4
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 4
- 125000003118 aryl group Chemical group 0.000 claims abstract 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract 4
- 229910052794 bromium Inorganic materials 0.000 claims abstract 4
- 229910052736 halogen Inorganic materials 0.000 claims abstract 4
- 150000002367 halogens Chemical class 0.000 claims abstract 4
- 239000000651 prodrug Substances 0.000 claims abstract 4
- 229940002612 prodrug Drugs 0.000 claims abstract 4
- 230000002285 radioactive effect Effects 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims abstract 2
- 125000006713 (C5-C10) cycloalkyl group Chemical group 0.000 claims abstract 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract 2
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 2
- 239000000460 chlorine Substances 0.000 claims abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 2
- 150000002148 esters Chemical group 0.000 claims abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 2
- 150000002431 hydrogen Chemical class 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 2
- 239000001257 hydrogen Substances 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 8
- 206010020850 Hyperthyroidism Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 208000019423 liver disease Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 208000019425 cirrhosis of liver Diseases 0.000 claims 4
- 208000006454 hepatitis Diseases 0.000 claims 4
- 208000017520 skin disease Diseases 0.000 claims 4
- 208000005057 thyrotoxicosis Diseases 0.000 claims 3
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 231100000354 acute hepatitis Toxicity 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- FHWUCNVBWYWJNU-UHFFFAOYSA-N 2-amino-3-[3,5-dibromo-4-(1,1,1,3,3,3-hexafluoro-2-phenylpropan-2-yl)oxyphenyl]propanoic acid Chemical compound BrC1=CC(CC(N)C(O)=O)=CC(Br)=C1OC(C(F)(F)F)(C(F)(F)F)C1=CC=CC=C1 FHWUCNVBWYWJNU-UHFFFAOYSA-N 0.000 claims 1
- JRXAEQVDYKZTQC-UHFFFAOYSA-N 2-amino-3-[3,5-dibromo-4-[(2-fluorophenyl)methoxy]phenyl]propanoic acid Chemical compound BrC1=CC(CC(N)C(O)=O)=CC(Br)=C1OCC1=CC=CC=C1F JRXAEQVDYKZTQC-UHFFFAOYSA-N 0.000 claims 1
- PMKPIJGWSZMONC-UHFFFAOYSA-N 2-amino-3-[3,5-dibromo-4-[(3,5-dimethylphenyl)methoxy]phenyl]propanoic acid Chemical compound CC1=CC(C)=CC(COC=2C(=CC(CC(N)C(O)=O)=CC=2Br)Br)=C1 PMKPIJGWSZMONC-UHFFFAOYSA-N 0.000 claims 1
- YXHDKWOBIOXQGD-UHFFFAOYSA-N 2-amino-3-[3,5-dibromo-4-[(3-bromophenyl)methoxy]phenyl]propanoic acid Chemical compound BrC1=CC(CC(N)C(O)=O)=CC(Br)=C1OCC1=CC=CC(Br)=C1 YXHDKWOBIOXQGD-UHFFFAOYSA-N 0.000 claims 1
- KFZXGYYQCWOBJF-UHFFFAOYSA-N 2-amino-3-[3,5-dibromo-4-[(3-iodophenyl)methoxy]phenyl]propanoic acid Chemical compound BrC1=CC(CC(N)C(O)=O)=CC(Br)=C1OCC1=CC=CC(I)=C1 KFZXGYYQCWOBJF-UHFFFAOYSA-N 0.000 claims 1
- LVCDFWXVNFJABC-UHFFFAOYSA-N 2-amino-3-[3,5-dibromo-4-[(5-methyl-1,2-oxazol-3-yl)methoxy]phenyl]propanoic acid Chemical compound O1C(C)=CC(COC=2C(=CC(CC(N)C(O)=O)=CC=2Br)Br)=N1 LVCDFWXVNFJABC-UHFFFAOYSA-N 0.000 claims 1
- OJNOZEYNUXPUNL-UHFFFAOYSA-N 2-amino-3-[3,5-dibromo-4-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]propanoic acid Chemical compound BrC1=CC(CC(N)C(O)=O)=CC(Br)=C1OCC1=CC=CC(C(F)(F)F)=C1 OJNOZEYNUXPUNL-UHFFFAOYSA-N 0.000 claims 1
- PEAAAFSXSYBQIV-UHFFFAOYSA-N 2-chloro-3-[3,5-dibromo-4-[(3-bromophenyl)methoxy]phenyl]propanoic acid Chemical compound BrC1=CC(CC(Cl)C(=O)O)=CC(Br)=C1OCC1=CC=CC(Br)=C1 PEAAAFSXSYBQIV-UHFFFAOYSA-N 0.000 claims 1
- FAVJFSWZYNDLOI-UHFFFAOYSA-N 3-[3,5-dibromo-4-(naphthalen-2-ylmethoxy)phenyl]-2-hydroxypropanoic acid Chemical compound BrC1=CC(CC(O)C(O)=O)=CC(Br)=C1OCC1=CC=C(C=CC=C2)C2=C1 FAVJFSWZYNDLOI-UHFFFAOYSA-N 0.000 claims 1
- ZWBRFAZKJLOFGY-UHFFFAOYSA-N 3-[3,5-dibromo-4-(pyridin-2-ylmethoxy)phenyl]-2-hydroxypropanoic acid Chemical compound BrC1=CC(CC(O)C(O)=O)=CC(Br)=C1OCC1=CC=CC=N1 ZWBRFAZKJLOFGY-UHFFFAOYSA-N 0.000 claims 1
- YDEALEVTVHDSAC-UHFFFAOYSA-N 3-[3,5-dibromo-4-[(3-bromophenyl)methoxy]phenyl]-2-hydroxypropanoic acid Chemical compound BrC1=CC(CC(O)C(O)=O)=CC(Br)=C1OCC1=CC=CC(Br)=C1 YDEALEVTVHDSAC-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 208000001348 Chloracne Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010020112 Hirsutism Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 241000101040 Pityriasis Species 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims 1
- 229930003316 Vitamin D Chemical class 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 206010021198 ichthyosis Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000001788 irregular Effects 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 230000003818 metabolic dysfunction Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- 239000005495 thyroid hormone Substances 0.000 claims 1
- 229940036555 thyroid hormone Drugs 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 208000003663 ventricular fibrillation Diseases 0.000 claims 1
- 206010047302 ventricular tachycardia Diseases 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Chemical class 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
- 0 *c(cc(cc1N)[Mn])c1O*(N)F Chemical compound *c(cc(cc1N)[Mn])c1O*(N)F 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0111861 | 2001-05-15 | ||
| GBGB0111861.1A GB0111861D0 (en) | 2001-05-15 | 2001-05-15 | Novel compounds |
| PCT/EP2002/004193 WO2002092550A1 (en) | 2001-05-15 | 2002-04-15 | Thyroid hormone receptor antagonists for cardiac and metabolic disorders ii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE02735262T1 true DE02735262T1 (de) | 2004-07-08 |
Family
ID=9914678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE0001387825T Pending DE02735262T1 (de) | 2001-05-15 | 2002-04-15 | Schilddrüsenhormon-rezeptor-antagonisten zur behandlung von herzerkrankungen & metabolischen störungen |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7319096B2 (enExample) |
| EP (1) | EP1387825A1 (enExample) |
| JP (1) | JP2004533450A (enExample) |
| KR (1) | KR20040017812A (enExample) |
| CN (1) | CN1275938C (enExample) |
| AU (1) | AU2002310850B2 (enExample) |
| CA (1) | CA2446747A1 (enExample) |
| DE (1) | DE02735262T1 (enExample) |
| GB (1) | GB0111861D0 (enExample) |
| IL (1) | IL158671A0 (enExample) |
| WO (1) | WO2002092550A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4705756B2 (ja) * | 2002-02-07 | 2011-06-22 | 仁 遠藤 | 芳香族アミノ酸誘導体及び医薬組成物 |
| GB0208384D0 (en) * | 2002-04-11 | 2002-05-22 | Karobio Ab | Novel compounds |
| EP1571144A4 (en) * | 2002-12-12 | 2007-08-01 | Kowa Co | HYDROXYALKYLATED CYCLIC DEDIAMINE COMPOUND |
| EP2428516A1 (en) * | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| WO2005054213A1 (ja) * | 2003-12-02 | 2005-06-16 | Shionogi & Co., Ltd. | ペルオキシソーム増殖活性化受容体アゴニスト活性を有するイソキサゾール誘導体 |
| GB0405033D0 (en) * | 2004-03-05 | 2004-04-07 | Karobio Ab | Novel pharmaceutical compositions |
| GB0406380D0 (en) * | 2004-03-22 | 2004-04-21 | Karobio Ab | Novel pharmaceutical compositions |
| DE102005003632A1 (de) | 2005-01-20 | 2006-08-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Katheter für die transvaskuläre Implantation von Herzklappenprothesen |
| US20090232879A1 (en) | 2005-05-26 | 2009-09-17 | Metabasis Therapeutics, Inc. | Thyromimetics for the Treatment of Fatty Liver Diseases |
| RU2007148927A (ru) * | 2005-05-26 | 2009-07-10 | Метабэйзис Терапьютикс, Инк. (Us) | Новые тиреомиметики, содержащие фосфиновую кислоту |
| US20070213813A1 (en) | 2005-12-22 | 2007-09-13 | Symetis Sa | Stent-valves for valve replacement and associated methods and systems for surgery |
| US7896915B2 (en) | 2007-04-13 | 2011-03-01 | Jenavalve Technology, Inc. | Medical device for treating a heart valve insufficiency |
| US9044318B2 (en) | 2008-02-26 | 2015-06-02 | Jenavalve Technology Gmbh | Stent for the positioning and anchoring of a valvular prosthesis |
| BR112012021347A2 (pt) | 2008-02-26 | 2019-09-24 | Jenavalve Tecnology Inc | stent para posicionamento e ancoragem de uma prótese valvular em um local de implantação no coração de um paciente |
| US10856978B2 (en) | 2010-05-20 | 2020-12-08 | Jenavalve Technology, Inc. | Catheter system |
| CA2799459A1 (en) | 2010-05-25 | 2011-12-01 | Jenavalve Technology Inc. | Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent |
| WO2015028209A1 (en) | 2013-08-30 | 2015-03-05 | Jenavalve Technology Gmbh | Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame |
| EP4353203B1 (en) | 2015-03-20 | 2026-08-19 | JenaValve Technology, Inc. | Heart valve prosthesis delivery system |
| EP3632378B1 (en) | 2015-05-01 | 2024-05-29 | JenaValve Technology, Inc. | Device with reduced pacemaker rate in heart valve replacement |
| WO2017195125A1 (en) | 2016-05-13 | 2017-11-16 | Jenavalve Technology, Inc. | Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system |
| WO2018094265A2 (en) | 2016-11-21 | 2018-05-24 | Viking Therapeutics, Inc. | Method of treating glycogen storage disease |
| EP3573579B1 (en) | 2017-01-27 | 2023-12-20 | JenaValve Technology, Inc. | Heart valve mimicry |
| AU2018280118B2 (en) | 2017-06-05 | 2021-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| EA202091979A1 (ru) | 2018-03-22 | 2021-06-22 | Вайкинг Терапьютикс, Инк. | Кристаллические формы и способы получения кристаллических форм соединения |
| EP4775207A2 (en) | 2018-12-05 | 2026-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| EP4161925A4 (en) | 2020-06-09 | 2024-09-04 | Viking Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES |
| WO2024102411A1 (en) | 2022-11-09 | 2024-05-16 | Jenavalve Technology, Inc. | Catheter system for sequential deployment of an expandable implant |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
| GB9816935D0 (en) | 1998-08-05 | 1998-09-30 | Karobio Ab | Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders |
| GB9927056D0 (en) | 1999-11-17 | 2000-01-12 | Karobio Ab | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
-
2001
- 2001-05-15 GB GBGB0111861.1A patent/GB0111861D0/en not_active Ceased
-
2002
- 2002-04-15 DE DE0001387825T patent/DE02735262T1/de active Pending
- 2002-04-15 EP EP02735262A patent/EP1387825A1/en not_active Withdrawn
- 2002-04-15 CN CNB028099419A patent/CN1275938C/zh not_active Expired - Fee Related
- 2002-04-15 JP JP2002589436A patent/JP2004533450A/ja active Pending
- 2002-04-15 US US10/477,676 patent/US7319096B2/en not_active Expired - Fee Related
- 2002-04-15 CA CA002446747A patent/CA2446747A1/en not_active Abandoned
- 2002-04-15 AU AU2002310850A patent/AU2002310850B2/en not_active Ceased
- 2002-04-15 WO PCT/EP2002/004193 patent/WO2002092550A1/en not_active Ceased
- 2002-04-15 IL IL15867102A patent/IL158671A0/xx unknown
- 2002-04-15 KR KR10-2003-7014840A patent/KR20040017812A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2446747A1 (en) | 2002-11-21 |
| US7319096B2 (en) | 2008-01-15 |
| EP1387825A1 (en) | 2004-02-11 |
| GB0111861D0 (en) | 2001-07-04 |
| KR20040017812A (ko) | 2004-02-27 |
| WO2002092550A1 (en) | 2002-11-21 |
| CN1509267A (zh) | 2004-06-30 |
| CN1275938C (zh) | 2006-09-20 |
| US20040220147A1 (en) | 2004-11-04 |
| AU2002310850B2 (en) | 2005-11-10 |
| JP2004533450A (ja) | 2004-11-04 |
| IL158671A0 (en) | 2004-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005522476A5 (enExample) | ||
| DE69813896T2 (de) | Alpha-aminoamidderivate die als analgetische mittel nützlich sind | |
| DE69705480T2 (de) | Verwendung von Oestrogenagonisten und -antagonisten zur Herstellung eines Medikaments zur Behandlung von Atherosklerose, unabhängig von Lipidsenkung | |
| CA2787114A1 (en) | Methods of treating meibomian gland dysfunction | |
| EP1640000A2 (de) | Pharmazeutische Zusammensetzung aus einem beta-3-Adrenozeptor-Agonisten und einem Serotonin- und/oder Norepinephrin-Reuptake-Inhibitor | |
| JP2004533450A5 (enExample) | ||
| DE60307258T2 (de) | Salze von Tolterodin | |
| WO2005060955A1 (de) | Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem in den prostaglandinstoffwechsel eingreifendem wirkstoff | |
| DE60317935T2 (de) | Alpha-aminoamid-derivate als mittel gegen migräne | |
| DE2707048A1 (de) | Neue indolizinderivate, verfahren zu deren herstellung, sowie diese enthaltende zusammensetzungen | |
| EP1682183A2 (de) | Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einem alpha antagonisten und/oder einen 5-alpha reduktase-hemmer | |
| DE60019322T2 (de) | Heteroatomunterbrochene analoge von15-hydroxyeicosatetraensäure und verfahren zu deren verwendung | |
| DE69922786T2 (de) | Verfahren zur Behandlung der chronischen obstruktiven Lungenerkrankung | |
| WO2002043715A2 (de) | Verwendung von 1-phenyl-3-dimethylamino-propanverbindungen zur therapie der harninkontinenz | |
| DE69828390T2 (de) | Antikrebs-zusammensetzung | |
| DE10352132A1 (de) | Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten | |
| EP1337246B1 (de) | Verwendung von 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz | |
| WO2002043714A2 (de) | Verwendung von substituierten 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz | |
| WO2005084675A1 (de) | Kv1.5-blocker zur selektiven steigerung der vorhofkontraktilität und behandlung der herzinsuffizienz | |
| DE60018647T2 (de) | Verwendung von 4,6-Dimethoxyindol-2-carbonsäure oder ihren Derivaten zur Behandlung von Seborrhoe | |
| DE69632078T2 (de) | 3-aminopropoxyphenyl-derivate | |
| DE10351271A1 (de) | Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz | |
| DE19705718A1 (de) | Neue Oxirancarbonsäuren zur Behandlung des Diabetes Typ 2 und anderer insulinresistenter Zustände | |
| DE10341233A1 (de) | Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien | |
| DE2406200A1 (de) | Verfahren zur herstellung von neuen 3,6-diamino-3,4-dihydropyridonen-2 und ihre verwendung als arzneimittel |